Pisano, C.; De Filippis, M.; Jacobs, F.; Novello, S.; Reale, M.L. Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements. Cancers2022, 14, 718.
Pisano, C.; De Filippis, M.; Jacobs, F.; Novello, S.; Reale, M.L. Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements. Cancers 2022, 14, 718.
Pisano, C.; De Filippis, M.; Jacobs, F.; Novello, S.; Reale, M.L. Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements. Cancers2022, 14, 718.
Pisano, C.; De Filippis, M.; Jacobs, F.; Novello, S.; Reale, M.L. Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements. Cancers 2022, 14, 718.
Abstract
Personalized treatment based on driver molecular alterations, such as ALK rearrangement, has revolutionized the therapeutic management of advanced oncogene addicted NSCLC patients. Multiple effective ALK tyrosine kinase inhibitors (TKIs), with the amelioration of the activity at central nervous system level, are now available, leading to substantial prognosis improvement. The exposure to TKIs triggers resistance mechanisms and the sequential administration of other TKIs and chemotherapy is, for the most part, not targeted. In this context, extending the benefit deriving from precision medicine is paramount, above all when disease progression occurs in a limited number of sites. Retrospective data indicate that, in oligoprogressive disease, targeted therapy beyond progression combined with definitive local treatment of the progressing site(s) is an effective alternative. In these cases, multidisciplinary approach becomes essential for an integrated treatment strategy, depending on the site of disease progression, in order to improve not only survival, but also quality of life. In this review we provide an updated and comprehensive overview of the main treatment strategies in case of ALK rearranged oligoprogression, including systemic treatment as well as local therapy, and report real-world clinical stories, with the final aim of identifying the most promising management for this subset of patients.
Keywords
oligoprogression; NSCLC; ALK rearrangement
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
